Quality of Life and AL Amyloidosis
Spencer Guthrie, Head of Medical Affairs at Prothena Biosciences summarizes 3 abstracts presented at the 58th Annual ASH Meeting & Exposition that examined a variety of aspects impacting quality of life measures in patients with AL Amyloidosis.
References
Sanchorawala V, McCausland K, Lo S, et al. 3586 Changes in Health-Related Quality of Life Corresponding to Hematologic Responses to Treatment in AL Amyloidosis. Presented at the 58th ASH Annual Meeting & Exposition; San Diego, CA: December 3-6, 2016. Abstract 3586.
Bayliss M, White MK, McCausland K, et al. Burden of AL Amyloidosis on Health-Related Quality of Life in Clinic-Based, Community-Based, and Trial-Based Studies. Presented at the 58th ASH Annual Meeting & Exposition; San Diego, CA: December 3-6, 2016. Abstract 3595.
Bayliss M, White MK, McCausland K, et al. Treatment-Related Symptoms and Impact on Health-Related Quality of Life in AL Amyloidosis. Presented at the 58th ASH Annual Meeting & Exposition; San Diego, CA: December 3-6, 2016. Abstract 4753.
-
Category
No comments found